Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.23
MNK's Cash to Debt is ranked higher than
52% of the 1152 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.37 vs. MNK: 0.23 )
MNK' s 10-Year Cash to Debt Range
Min: 0.15   Max: 0.31
Current: 0.23

0.15
0.31
Equity to Asset 0.40
MNK's Equity to Asset is ranked higher than
54% of the 1034 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.58 vs. MNK: 0.40 )
MNK' s 10-Year Equity to Asset Range
Min: 0.25   Max: 0.4
Current: 0.4

0.25
0.4
Z-Score: 1.31
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -8.02
MNK's Operating margin (%) is ranked higher than
54% of the 1102 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.84 vs. MNK: -8.02 )
MNK' s 10-Year Operating margin (%) Range
Min: -11.18   Max: 6.57
Current: -8.02

-11.18
6.57
Net-margin (%) -9.50
MNK's Net-margin (%) is ranked higher than
54% of the 1102 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.10 vs. MNK: -9.50 )
MNK' s 10-Year Net-margin (%) Range
Min: -12.57   Max: 2.67
Current: -9.5

-12.57
2.67
ROE (%) -9.72
MNK's ROE (%) is ranked higher than
55% of the 1129 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.93 vs. MNK: -9.72 )
MNK' s 10-Year ROE (%) Range
Min: -10.28   Max: -10.28
Current: -9.72

ROA (%) -3.40
MNK's ROA (%) is ranked higher than
57% of the 1161 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.32 vs. MNK: -3.40 )
MNK' s 10-Year ROA (%) Range
Min: -3.89   Max: -3.89
Current: -3.4

ROC (Joel Greenblatt) (%) -14.84
MNK's ROC (Joel Greenblatt) (%) is ranked higher than
56% of the 1156 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.14 vs. MNK: -14.84 )
MNK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -39.77   Max: -39.77
Current: -14.84

» MNK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

MNK Guru Trades in Q2 2014

Richard Perry 134,322 sh (New)
Mario Gabelli 2,656 sh (New)
Chase Coleman 729,373 sh (New)
Paul Singer 916,000 sh (New)
Jana Partners 5,725,711 sh (+75.22%)
John Paulson 6,724,800 sh (+19.30%)
John Paulson 6,724,800 sh (+19.30%)
Jean-Marie Eveillard 187 sh (unchged)
Chuck Royce Sold Out
Pioneer Investments 120,663 sh (-0.68%)
Jim Simons 238,900 sh (-5.98%)
Paul Tudor Jones 308,900 sh (-14.22%)
» More
Q3 2014

MNK Guru Trades in Q3 2014

Steven Cohen 31,900 sh (New)
Chuck Royce 23,407 sh (New)
Joel Greenblatt 115,541 sh (New)
John Hussman 67,275 sh (New)
Richard Perry 1,150,000 sh (+756.15%)
Mario Gabelli 7,134 sh (+168.60%)
Jim Simons 359,502 sh (+50.48%)
John Paulson 9,000,000 sh (+33.83%)
Jean-Marie Eveillard 187 sh (unchged)
Pioneer Investments 120,582 sh (unchged)
Chase Coleman Sold Out
Paul Singer Sold Out
Jana Partners Sold Out
Paul Tudor Jones 24,849 sh (-91.96%)
» More
Q4 2014

MNK Guru Trades in Q4 2014

Louis Moore Bacon 14,363 sh (New)
RS Investment Management 34,500 sh (New)
Pioneer Investments 1,418,356 sh (+1076.26%)
Mario Gabelli 7,922 sh (+11.05%)
John Paulson 9,012,293 sh (+0.14%)
John Hussman 67,275 sh (unchged)
Jean-Marie Eveillard 187 sh (unchged)
Richard Perry Sold Out
Chuck Royce Sold Out
Steven Cohen 31,700 sh (-0.63%)
Joel Greenblatt 110,019 sh (-4.78%)
Jim Simons 117,502 sh (-67.32%)
Paul Tudor Jones 2,184 sh (-91.21%)
» More
Q1 2015

MNK Guru Trades in Q1 2015

Mario Gabelli 7,122 sh (-10.10%)
John Hussman 25,000 sh (-62.84%)
» More
» Details

Insider Trades

Latest Guru Trades with MNK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 24.39
MNK's Forward P/E is ranked higher than
80% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. MNK: 24.39 )
N/A
P/B 2.60
MNK's P/B is ranked higher than
73% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.13 vs. MNK: 2.60 )
MNK' s 10-Year P/B Range
Min: 1   Max: 3.59
Current: 2.6

1
3.59
P/S 3.16
MNK's P/S is ranked higher than
65% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.19 vs. MNK: 3.16 )
MNK' s 10-Year P/S Range
Min: 1.59   Max: 3.55
Current: 3.16

1.59
3.55
PFCF 22.60
MNK's PFCF is ranked higher than
89% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. MNK: 22.60 )
MNK' s 10-Year PFCF Range
Min: 18.94   Max: 28.48
Current: 22.6

18.94
28.48
POCF 17.06
MNK's POCF is ranked higher than
87% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 45.91 vs. MNK: 17.06 )
MNK' s 10-Year POCF Range
Min: 12.38   Max: 19.6
Current: 17.06

12.38
19.6
EV-to-EBIT -74.29
MNK's EV-to-EBIT is ranked lower than
60% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 43.18 vs. MNK: -74.29 )
MNK' s 10-Year EV-to-EBIT Range
Min: -80.4   Max: 52.1
Current: -74.29

-80.4
52.1
Current Ratio 2.70
MNK's Current Ratio is ranked higher than
76% of the 1100 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.13 vs. MNK: 2.70 )
MNK' s 10-Year Current Ratio Range
Min: 2.29   Max: 2.7
Current: 2.7

2.29
2.7
Quick Ratio 2.22
MNK's Quick Ratio is ranked higher than
78% of the 1100 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.60 vs. MNK: 2.22 )
MNK' s 10-Year Quick Ratio Range
Min: 1.5   Max: 2.22
Current: 2.22

1.5
2.22
Days Inventory 100.49
MNK's Days Inventory is ranked higher than
80% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 148.81 vs. MNK: 100.49 )
MNK' s 10-Year Days Inventory Range
Min: 109.13   Max: 109.13
Current: 100.49

Days Sales Outstanding 64.75
MNK's Days Sales Outstanding is ranked higher than
79% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 89.68 vs. MNK: 64.75 )
MNK' s 10-Year Days Sales Outstanding Range
Min: 66.36   Max: 78.39
Current: 64.75

66.36
78.39

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.40
MNK's Price/Median PS Value is ranked higher than
66% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.60 vs. MNK: 1.40 )
MNK' s 10-Year Price/Median PS Value Range
Min: 0.62   Max: 1.19
Current: 1.4

0.62
1.19
Earnings Yield (Greenblatt) -1.30
MNK's Earnings Yield (Greenblatt) is ranked higher than
54% of the 1148 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. MNK: -1.30 )
MNK' s 10-Year Earnings Yield (Greenblatt) Range
Min: -1.3   Max: 2.4
Current: -1.3

-1.3
2.4

Analyst Estimate

Sep15 Sep16 Sep17
Revenue(Mil) 3,713 3,979 4,322
EPS($) 7.43 4.69 9.98
EPS without NRI($) 7.43 4.69 9.98

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:MCD.Germany,
Mallinckrodt PLC develops, manufactures, markets and distributes specialty pharmaceutical products and diagnostic imaging agents. Its specialty pharmaceutical products are sold to wholesalers and retail drugstore chains. The Company's Specialty Pharmaceuticals segment includes branded and generic drugs, and the Global Medical Imaging segment includes contrast media and nuclear imaging agents. The Company's products include Intrathecal Product used in the management of cerebral or spinal spasticity. The Company's nonsteroidal anti-inflammatory drug (NSAID) portfolio helps address the signs and symptoms of painful condition. PENNSAID, is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of signs and symptoms of osteoarthritis of the knee(s). The Opioid products include EXALGO. It is an Extended-Release Tablets indicated for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time. The Central Nervous Systems' products include Anafranil, indicated for the treatment of obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD). The Global Medical Imaging products includes Optisuite, Optibolus Bolus Shaping Software, Ready-Box, Ultra-Technekow DTE Generator, Octreoscan, and Technescan MAG3.
» More Articles for MNK

Headlines

Articles On GuruFocus.com
Only Buy Luxury At A Deep Discount Apr 01 2015 
Mallinckrodt Has Brighter Days Going Ahead Mar 10 2015 
Paulson Bets Again On Mallinckrodt Aug 07 2014 
Dumb Investment of the Week: Mallinckrodt PLC Jul 17 2014 
Mallinckrodt Acquired San Diego Pharma and Much More Mar 21 2014 
Can Malllinckrodt Keep on Crushing Expectations? Mar 19 2014 
Should You Buy Actavis? Mar 18 2014 
Weekly 3-Year Low Highlight: EW, NUAN, MNK, CROX, IRDM Nov 03 2013 

More From Other Websites
15 Companies Losing the Most Money May 01 2015
Mallinckrodt Pharmaceuticals Becomes First-Ever National Sponsor of the Lupus Foundation of... May 01 2015
Three Top Stocks Shape New Bases Ahead Of Earnings Apr 27 2015
Teva-Active Biotech Start Phase II on MS Drug - Analyst Blog Apr 24 2015
Mallinckrodt To Present At Deutsche Bank Healthcare Conference Apr 22 2015
Mallinckrodt To Present At Deutsche Bank Healthcare Conference Apr 22 2015
Akorn Leads Top Generic-Drug Stocks, Nears Buy Point Apr 20 2015
Novartis and Momenta Get FDA Nod For Generic Copaxone - Analyst Blog Apr 17 2015
Pacira Down on Subpoena on Exparel Marketing Issues - Analyst Blog Apr 17 2015
Mallinckrodt details management shift in Ikaria merger Apr 17 2015
MALLINCKRODT PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of... Apr 17 2015
High-Yield Bond Funds See Inflows Pick Up Pace in April 10 Week Apr 16 2015
Mallinckrodt Completes Acquisition Of Ikaria Apr 16 2015
Mallinckrodt Completes Acquisition Of Ikaria Apr 16 2015
United Therapeutics Corporation (UTHR), Amgen, Inc. (AMGN): Neil Shah’s Top Healthcare Picks... Apr 16 2015
Fiat Chrysler, GM Financial Issue Largest Bonds in April 10 Week Apr 16 2015
Roche Collaborates with Astellas Pharma for Tissue Diagnostics - Analyst Blog Apr 15 2015
Abbott Labs, Sekisui Medical to Offer Coagulation Tests - Analyst Blog Apr 15 2015
High-Yield Debt Issuance Gathers Steam in Week to April 10 Apr 15 2015
Mallinckrodt Pharmaceuticals to Sponsor the National Kidney Foundation Kidney Walk Apr 14 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK